C16orf72

Across TCGA pan-cancer cohorts, C16orf72 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C16orf72 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher C16orf72 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C16orf72 expression acts as an unfavorable survival marker.

KIRP, BLCA, and PRAD are the cancer types where C16orf72 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	II,III,IV	0.037	0.783	<.001	20	view →
BLCA	OS	Median	All	0.228	0.720	.010	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C16orf72–KIRP (DFS)

Open the KIRP breakdown →